博晖创新(300318) - 2022 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2022 was CNY 214,100,881.83, representing a 16.79% increase year-over-year[5] - The net profit attributable to shareholders was CNY -19,539,556.10, a decrease of 61.75% compared to the same period last year[5] - The basic earnings per share for Q3 2022 was CNY -0.0239, down 61.49% year-over-year[5] - Total operating revenue for Q3 2022 was CNY 597,413,453.96, an increase of 12.3% compared to CNY 532,011,776.18 in the same period last year[22] - The net loss for the period was CNY 141,289,756.46, compared to a loss of CNY 101,970,958.00 in the previous year[21] - The net profit for the third quarter of 2022 was -88,301,832.21 CNY, compared to -76,486,558.47 CNY in the same period last year, representing an increase in net loss of approximately 15.5%[24] - The total comprehensive income for the third quarter was -84,160,488.27 CNY, compared to -76,612,587.69 CNY in the previous year, indicating a decline of about 9.5%[25] - The basic and diluted earnings per share were both -0.0481 CNY, compared to -0.0345 CNY in the same quarter last year, reflecting a worsening in earnings per share[25] - The company reported operating income of -79,895,791.55 CNY, compared to -68,933,560.22 CNY in the previous year, indicating a decline in operational performance[24] Assets and Liabilities - Total assets as of September 30, 2022, amounted to CNY 3,786,708,493.43, reflecting a 2.62% increase from the end of the previous year[5] - The company's total assets reached CNY 3,786,708,493.43, up from CNY 3,690,026,740.04, marking an increase of 2.6%[21] - The company's inventory increased to CNY 870,267,070.51, compared to CNY 820,953,599.87 in the previous quarter, indicating a rise of 6.0%[20] - Current assets totaled CNY 1,139,764,246.69, a slight increase from CNY 1,079,561,139.20, representing a growth of 5.6%[20] - Non-current assets amounted to CNY 2,646,944,246.74, compared to CNY 2,610,465,600.84, showing an increase of 1.4%[20] - The total liabilities decreased to CNY 1,412,705,737.13 from CNY 2,757,281,706.76, indicating a significant reduction of 48.9%[21] Cash Flow - The company's cash flow from operating activities showed a net outflow of CNY -28,327,997.49, a significant decline of 762.56%[5] - Cash flow from operating activities showed a net outflow of -28,327,997.49 CNY, compared to -3,284,164.08 CNY in the previous year, indicating a significant increase in cash outflow[26] - Cash flow from investing activities resulted in a net outflow of -70,479,138.29 CNY, compared to -309,901,057.83 CNY in the same period last year, showing an improvement in cash flow management[26] - Cash flow from financing activities generated a net inflow of 161,112,292.32 CNY, compared to 316,646,291.12 CNY in the previous year, indicating a decrease in financing activities[26] - The total cash and cash equivalents at the end of the period were 96,772,123.51 CNY, up from 46,488,862.00 CNY in the same period last year, reflecting a significant increase in liquidity[27] Operating Costs and Income - The company's operating costs rose by 32.51% to CNY 402,266,913.38, mainly due to increased plasma costs for blood products[10] - Total operating costs for Q3 2022 were CNY 679,084,214.56, up from CNY 614,587,565.43, reflecting a year-over-year increase of 10.5%[22] - Cash paid for purchasing goods and services rose by 32.46% year-on-year to ¥328,767,778.93, attributed to higher raw material procurement costs[11] Borrowings and Equity - The company's long-term borrowings increased by 281.62% to CNY 318,948,848.69, primarily due to project loans obtained by a subsidiary[9] - The capital reserve increased by 189.24% to CNY 754,221,087.47, attributed to the completion of a capital increase by a subsidiary[9] - The company's total equity attributable to shareholders increased by 47.02% to CNY 1,433,035,511.19 compared to the end of the previous year[5] - The company reported a significant increase in short-term borrowings, which rose to CNY 445,085,342.79 from CNY 434,893,006.77, an increase of 2.7%[21] Other Income and Expenses - Other income decreased by 67.68% to CNY 3,323,801.90, primarily due to a reduction in government subsidies received[10] - Research and development expenses for Q3 2022 were CNY 46,029,182.64, slightly down from CNY 49,792,899.26, reflecting a decrease of 5.5%[22] - The company recorded asset impairment losses of -92,551.36 CNY, which remained unchanged from the previous year[24] New Products and Partnerships - The company launched multiple new products, including various IgE antibody testing kits, which received medical device registration certificates[15] - The company signed guarantee contracts with Bank of Communications for a maximum amount of ¥41.6 million, indicating ongoing financial partnerships[16] Cash Inflows - Cash received from other operating activities increased by 42.67% year-on-year to ¥32,113,751.91, primarily due to an increase in deposits received[11] - Cash received from investment activities was ¥49,903,088.15, a significant increase of 168.02% year-on-year, reflecting the inclusion of tax refunds in investment cash flows[11] - The company raised ¥378,421,949.70 from minority shareholders during the reporting period, a new source of cash inflow[11] - Cash received from bank borrowings increased by 34.68% year-on-year to ¥672,043,149.41, indicating a rise in financing activities[11]